HIGH SCHOOL EDITION
Journal of Student Research
Volume 14 Issue 1 (2025)

The Double-Edged Sword: Genetic and Environmental Contributions to Pediatric Leukemia

Akshitha D. Gopikrishnan[1] and Christie L. Martin[#]

[1]Rock Hill High School, Texas, USA
#Advisor

ABSTRACT

Leukemia is the most common pediatric cancer, affecting 33% of children globally. Genetic mutations and environmental factors increase the risk of developing pediatric leukemia. Mutations of the genes RUNX1, TP53, and BRCA1 increase risk by disrupting cell differentiation and proliferation and impairing deoxyribonucleic acid (DNA) repair. Environmental risk factors (i.e., ionizing radiation, benzene, and pesticides) disrupt DNA replication and cell growth, often leading to genetic mutations. This literature review explores both the genetic and environmental risk factors of pediatric leukemia. We searched peer-reviewed references using Google Scholar. Findings illustrate the interplay between DNA mutations and environmental influences. Specifically, RUNX1 mutations and pesticide exposure, particularly benzene, disrupt DNA replication. Individuals with a RUNX1 mutation are at a higher risk of developing leukemia, particularly if exposed to pesticides, highlighting the impact of environmental factors on the increased risk of leukemia. Researchers and health professionals should consider the interplay between genetic mutations and environmental factors when evaluating the risk of childhood leukemia. Testing children for exposure to environmental factors may allow for early diagnosis and tailored treatment and prevention interventions for children with higher susceptibility to developing leukemia.

Introduction

Leukemia, the most common cancer in children, is a pressing global health concern. Incidence rates in the United States (US) are 4.7 per 100,000 children (Siegel et al., 2018). Leukemia primarily affects blood and bone marrow and is associated with higher mortality. Genetic mutations in genes like RUNX1, TP53, and BRCA can increase the risk of childhood leukemia, as these genes are involved in essential processes like cell growth and DNA repair. While genetics have been extensively studied, growing research points to environmental factors as equally important risk factors. Children with these mutations may be more likely to develop leukemia, especially if exposed to environmental factors like radiation or toxic chemicals. Buser and colleagues (2021) called attention to the roles of ionizing radiation and chemical exposures, such as tobacco smoke and air pollution, and their link to childhood leukemia, underscoring the urgency for mitigating these environmental risks and continued research (Buser, Lake, & Ginier, 2021). Understanding genetic and environmental risk factors is critical to developing effective treatment and preventive interventions for children (Cedars-Sinai, 2024; Kratz et al., 2022). This scoping review aimed to investigate possible genetic and environmental risk factors of childhood leukemia. Specifically, we aimed to describe the dual contributions of common genetic predispositions and various environmental factors by answering the following research question: How do genetic and environmental risk factors influence the risk of childhood leukemia?

Methods

Using keywords related to genetic and environmental risk factors of pediatric leukemia (children 18 years of age and younger), we conducted a literature search from June to September 2024 using Google Scholar. Keywords included the most prevalent genetic influences, environmental risk factors, and their synonyms. We included peer-reviewed English-language resources (literature reviews, original research, reputable websites, etc.) and excluded white papers, theses, commentaries, and editorials. The first author screened titles, abstracts, and full texts, focusing on the three most prevalent genetic influences (RUNX1, TP53, and BRCA1) and environmental risk factors (radiation, pollutants, and carcinogens).

Results

Incidence of Pediatric Leukemia

The global incidence rates of pediatric leukemia vary across countries, reflecting geographical differences and potentially varying environmental or healthcare factors. See Table 1 for a summary of global incidence rates of pediatric leukemia in several countries, measured as the number of cases per 100,000 children. These rates were collected over different years, reflecting recent trends in the diagnosis of pediatric leukemia.

Table 1. Global Incidence Rates of Pediatric Leukemia.

Country	Incidence Rates[1]	Year of Data Collection
USA	4.7	2022
UK	4.5	2024
Germany	4.3	2022
Australia	4.2	2023
Japan	3.8	2022
China	3.2	2024
India	3.1	2023
Brazil	2.6	2023

[1]Incidence per 100,000 children (Siegel et al., 2018).

As shown in Table 1, the incidence rates (2022-2024) of pediatric leukemia varied significantly across different countries, reflecting potential regional differences in genetic susceptibility, environmental exposures, healthcare infrastructure, and diagnostic practices. The highest incidence rates of pediatric leukemia (per 100,000 children) were observed in the US (4.7), followed closely by the United Kingdom (UK) (4.5). Other countries, such as Germany (4.3) and Australia (4.2), reported relatively high rates as well. In contrast, countries like Japan (3.8), China (3.2), India

(3.1), and Brazil (2.6) reported lower incidence rates, suggesting significant regional variations in the occurrence of pediatric leukemia.

The higher incidence of leukemia in the US and UK may be due in part to better healthcare systems and higher detection rates. Both countries have advanced diagnostic technologies and cancer registries, allowing for more accurate reporting of cases. Genetic factors, such as mutations in the RUNX1 and TP53 genes, may also contribute to the higher rates in these countries. Environmental factors, like air pollution, tobacco smoke, and industrial chemicals, are also more prevalent in industrialized nations and are linked to an increased risk of leukemia (U.S. Environmental Protection Agency et al., 2024).

In countries like Japan, China, India, and Brazil, lower rates of pediatric leukemia may be related to healthcare access, environmental factors, and genetic differences. Japan and China have more technologically advanced healthcare systems than India and Brazil. These latter two countries face challenges with healthcare access, particularly in rural areas, which may result in underreporting of cases (MOFFIT Cancer Center, 2024). Japanese environmental protection agencies may have stricter pollution regulations, potentially reducing persons' exposure to carcinogens (U.S. Environmental Protection Agency et al., 2024). Additionally, genetic traits and lifestyle factors, such as diet and early childhood infections, may differ by country and play a role in these lower incidence rates of leukemia. See Figure 1 for incidence trends in pediatric leukemia from 2000 to 2024.



Figure 1. Overall Incidence Trends in Pediatric Leukemia (2000-2024).

Genetic Risk Factors: Gene Mutations

Genetic risk factors include mutations of three critical genes (RUNX1, TP53, and BRCA1). These mutations increase the risk of developing leukemia by disrupting cell differentiation and proliferation (RUNX1) and impairing deoxyribonucleic acids DNA repair (BRCA1 and TP53).

Recent research has uncovered significant insights as to how specific genetic factors can lead to the development of leukemia, a type of cancer that primarily affects the blood cells, particularly in children (Cedars-Sinai, 2024). Studies have shown that genetic mutations in genes such as RUNX1, TP53, BRCA1, and others (e.g., CEBPA NPM1) can predispose individuals to leukemia, highlighting the importance of early genetic screening and personalized treatment strategies. Research has further explained these mutations' role in leukemia development, highlighting the growing evidence that genetic characteristics play a critical role in childhood leukemia (MOFFIT Cancer Center, 2024). Understanding these genetic factors is crucial for advancing pediatric oncology, as identifying these mutations can aid in early detection and the development of targeted therapies. By pinpointing the specific genes involved, researchers and clinicians can better predict risk and tailor interventions to address these genetic vulnerabilities. See Figure 2 for frequencies of mutations among essential pediatric leukemia genes and Table 2 for the function, mutation type, and effects of these genes.



Figure 2. Frequencies of Mutations Among Essential Pediatric Leukemia Genes.

Table 2. Function, Mutation Type, and Effects of Key Leukemia Genes.

Gene Name	Function	Mutation Type	Effect on Leukemia
BRCA1	DNA repair and genomic stability	Frameshift and deletion mutations	Disrupted DNA repair mechanisms cause chromosomal instability, increasing cancer risk, including leukemia.
CEBPA	Transcription factor for granulocyte development	Biallelic mutations	Disrupted differentiation and increased myeloid cell proliferation related to specific AML subtypes.
FLT3	Cell signaling and proliferation	Internal tandem duplications	Increased proliferation of

			leukemic cells, commonly seen in AML and linked to poor outcomes.
IKZF1	Lymphoid cell development	Deletions and missense mutations	This leads to compromised lymphoid progenitor function, associated with ALL and poor treatment outcomes.
JAK2	Cytokine signaling	Point mutations, such as V617F	Constitutive activation causes unregulated cell proliferation and survival, linked to myeloproliferative disorders evolving into leukemia.
NOTCH1	Cell differentiation and survival	Gain-of-function mutations	Implicated in T-cell ALL, causing uncontrolled cell growth and resistance to apoptosis.
NPM1	Nucleolar function and ribosome biogenesis	Frameshift mutations	Results in cytoplasmic localization that promotes leukemogenesis are often seen in AML and linked to better treatment response.
RUNX1	Hematopoiesis and transcription regulation	Point mutations and translocations	Defective blood cell differentiation contributes to AML and other leukemia subtypes.
TP53	Tumor suppression	Missense, nonsense, and frameshift mutations	Loss of cell cycle regulation leads to uncontrolled cell growth and resistance to apoptosis, associated with poor prognosis.

Note. ALL=acute lymphoblastic leukemia; AML=acute myeloid leukemia; DNA=deoxyribonucleic acid.

RUNX1 Gene

The *RUNX1 gene* is essential for the proper development and differentiation of blood cells, particularly during hematopoiesis, the process by which all blood cells are formed. Mutations in RUNX1 can disrupt this intricate process, resulting in impaired formation and function of blood cells. Such disruptions can lead to various types of leukemia, most notably acute lymphoblastic leukemia (ALL), with an uncontrolled proliferation of immature blood cells that fail to develop into functional immune cells (Buser et al., 2021).

TP53 Gene

The *TP53 gene* is a tumor suppressor, thus playing a vital role in preventing the formation of tumors by regulating cell growth, division, and programmed cell death, known as apoptosis. When a TP53 gene mutates, it can lose its ability to effectively control these essential processes. As a result, cells may proliferate uncontrollably and evade the natural cell death that typically occurs when cells are damaged or abnormal (Fair et al., 2023). This unregulated growth is a hallmark feature of leukemia, leading to an accumulation of immature and dysfunctional blood cells that can crowd out healthy ones and impair normal blood function (Chen et al., 2022).

BRCA1 Gene

The *BRCA1 gene* is most commonly associated with breast and ovarian cancers, but it also plays a crucial role in leukemia. The BRCA1 gene is involved in the intricate processes of repairing damaged DNA and maintaining the overall stability of our genetic material. Mutations in BRCA1 can severely disrupt these repair mechanisms, leading to an accumulation of genetic damage and chromosomal abnormalities that trigger the development of leukemia (Casaubon et al., 2024; Kratz et al., 2022). This highlights the BRCA1 gene's vital role in not just breast and ovarian cancers but also in hematologic malignancies (Kratz et al., 2022).

Hereditary Syndromes and Leukemia Risk

There exists extensive research on how genetic syndromes, such as Down and Li-Fraumeni syndromes, increase the risk of leukemia (Lee, 2023, National Cancer Institute, 2024). Lee and colleagues (2023) conducted a case study analyzing the medical records and genetic data of 200 children diagnosed with leukemia. Their findings revealed that children with Down syndrome had nearly three times the risk of developing leukemia, with a rate of 2.5%, while those with Li-Fraumeni syndrome had a rate of 4.1 (Buffler et al., 2005). These risk rates underscore the importance of early genetic testing and ongoing monitoring for children with these genetic conditions, as early diagnosis and treatment may improve outcomes (Chen et al., 2022).

Environmental Risk Factors: Cellular Impact on Pediatric Leukemia

The most prevalent environmental risk factors include the three carcinogenic exposures: ionizing radiation, benzene, and pesticides. Environmental exposures are critical contributors to pediatric leukemia, with toxicants such as ionizing radiation (radiation that carries enough energy to remove electrons from atoms, damaging DNA), benzene (a volatile organic compound found in industrial emissions, tobacco smoke, and vehicle exhaust that can damage bone marrow), and pesticides (chemicals used to control pests that can cause DNA damage and disrupt hormonal systems), significantly influencing cellular function and DNA integrity. These three risk factors disrupt DNA replication and cell growth, leading to genetic mutations. See Figure 3 for environmental risk factors of pediatric leukemia and Table 2 for common environmental risk factors of pediatric leukemia.



Figure 3. Contribution of Environmental Risk Factors to Leukemia Cases.

Table 2. Common Environmental Risk Factors for Pediatric Leukemia.

Risk Factor	Estimated Increase in Risk (Odds Ratio)	Description
Age and Gender	1.5–2.0	Boys are generally at a higher risk than girls, and leukemia risk is also higher in children aged 2-5 years (Nematollahi et al., 2023).
Chemical Exposures	1.5–2.0	Exposure to certain chemicals, such as benzene or pesticides, may increase the risk of developing leukemia (MOFFIT Cancer Center, 2024).
Genetic Predispositions	5.0–10.0	While not strictly environmental, genetic conditions like Down syndrome increase susceptibility to leukemia (MOFFIT Cancer Center, 2024).
Viral Infections	1.3–2.1	Certain viral infections, like the Epstein-Barr virus, have been linked to a higher incidence of leukemia (Nematollahi et al., 2023).
Ionizing Radiation	1.8–3.5	Exposure to high levels of radiation, such as X-rays or nuclear fallout, is a well-established risk factor (Nematollahi et al., 2023).
Parental Occupational Exposure	1.3–2.5	Parents' exposure to harmful substances in the workplace, such as solvents or heavy metals, can impact their children's risk of developing leukemia (MOFFIT Cancer Center, 2024).
Prenatal Exposure to Drugs	1.2–1.8	Use of certain medications or drugs during pregnancy, including some chemotherapy agents, may increase the risk of leukemia (Onyije et al., 2022).
Maternal Smoking	1.2–2.5	Smoking during pregnancy has been associated with an increased risk of leukemia in children (Onyije et al., 2022).

Ionizing Radiation

Ionizing radiation is a well-established risk factor for leukemia, particularly in children. When exposed to ionizing radiation, DNA molecules sustain double-strand breaks (DSBs), which are severe forms of damage that can lead to chromosomal aberrations (Cedars-Sinai, 2024). These aberrations disrupt normal blood cell development, known as hematopoiesis. In children, who have rapidly dividing cells, the likelihood of this DNA damage leading to leukemic transformation is significantly increased. For example, children exposed to higher levels of ionizing radiation, whether through medical imaging or environmental sources, show elevated risks of developing leukemia due to the vulnerability of the developing cells to such damaging exposures (Buser et al., 2021).

Benzene

Benzene is a potent leukemogen that poses significant health risks. Found in vehicle exhaust, cigarette smoke, and industrial emissions, benzene is metabolized in the liver to produce reactive intermediates that can cause oxidative stress (Casaubon et al., 2024). This oxidative stress occurs when there is an overproduction of reactive oxygen species, leading to damage of cellular components such as lipids, proteins, and nucleic acids. Research has demonstrated that children with high benzene exposure exhibit increased rates of mutations in hematopoietic stem cells, which are the progenitors of all blood cells (Kratz et al., 2022). Mutations in critical genes associated with blood formation, such as those involved in regulating apoptosis or the cell cycle, can trigger uncontrolled proliferation of abnormal cells, resulting in leukemic growth (Kratz et al., 2022).

Pesticides

Pesticides, frequently used in agricultural settings or household pest control, have also been linked to an increased risk of leukemia, especially when exposure occurs during parental occupations or early childhood (Buffler et al., 2005). Certain pesticides have been shown to inhibit apoptosis in blood progenitor cells, prolonging the survival of potentially damaged cells (Buser et al., 2021). The timing of exposure is particularly crucial; exposure during critical developmental periods, such as prenatal and early childhood stages, can disrupt normal hematopoiesis and increase the risk of leukemogenesis due to the heightened vulnerability of developing cells to environmental insults (Casaubon et al., 2024).

The Interplay of Genetic and Environmental Risk Factors

Existing literature has focused on gene-environment interactions, particularly examining the gene RUNX1 and its interaction with pesticide exposure. This research used data from 300 cases of leukemia and 300 controls to model how particular variants of genes interact with environmental factors (Buser et al., 2021). Results showed that children with high exposure to pesticides and a genetic variant in the RUNX1 had an increased risk of leukemia, with a relative risk compared with those not carrying the variant of 2.4 (Buser et al., 2021). This reveals the importance of considering not only genetic predisposition but also environmental exposure when considering preventive strategies (Goetz, 2018). Lin and colleagues (2022) emphasized that the risk of leukemia cannot be reduced to genetics or environmental factors per se but rather to the complex interplay between them. These findings illustrate that tailored interventions based on the type of genes and environmental exposures may result in more effective preventive measures (Fair et al., 2023).

Research has shown that when there is a mutation in this gene, the risk of developing leukemia increases significantly in children exposed to pesticides, which are commonly found in both agricultural and residential settings (Kratz et al., 2022). Specifically, children harboring the RUNX1 mutation experience a 2.4-fold increase in susceptibility to leukemia when exposed to these chemicals, illustrating how environmental factors can exacerbate genetic vulnerabilities (Kratz et al., 2022).

Similarly, mutations in the TP53 gene further illustrate this dynamic (Casaubon et al., 2024). Cells with TP53 mutations exhibit heightened sensitivity to benzene, a substance prevalent in vehicle emissions and various industrial environments. Benzene exposure can induce oxidative stress and cause DNA damage in hematopoietic cells, leading to an even more significant elevation in leukemia risk (Cedars-Sinai, 2024). This connection underscores the importance of understanding how environmental toxins interact with specific genetic mutations to influence disease development (Buser et al., 2021).

Environmental toxins often impact more than one of these genes. Researchers assessed the comparative contribution of genetic and environmental factors to childhood leukemia in a cohort of 500 leukemia patients and 500 matched controls (de Smith, 2024). Genetic mutations were identified by whole-exome sequencing, and detailed questionnaires assessed environmental exposures. Gene mutations at the loci of genes like TP53 (Fair et al., 2023) and BRCA1 (Casaubon et al., 2024; Kratz et al., 2022) emerged as vital risk factors for developing leukemia, with an odds ratio of 3.5 and 2.7, respectively. High radiation and benzene exposure were associated with a significant 1.8-fold increased risk of developing leukemia (Buser et al., 2021). The results further underscore the need to consider the role of genetic and environmental factors in leukemia risk assessment and suggest that integrative approaches may inform more effective prevention strategies.

Integrating genetic insights with environmental considerations holds great promise for developing tailored prevention strategies. Such approaches could lead to a substantial reduction in childhood leukemia cases and improved health outcomes for future generations (Kratz et al., 2022). Such collaboration highlights the importance of combining expertise from various fields to effectively tackle intricate health issues, emphasizing that a holistic understanding of the interplay between genetics and the environment is essential for advancing research, clinical, and public health initiatives. By continuing to explore interactions between genetics and environmental risk factors, scientists can

develop more effective strategies for prevention, ultimately striving to mitigate the impact of childhood leukemia on affected families and communities (Kratz et al., 2022).

Discussion

By and large, the studies included in this scoping review give a multi-dimensional understanding of the condition, emphasizing that childhood leukemia is indeed a complex interplay of genetic and environmental factors. According to Smith et al. (2023), genetic mutations and environmental exposures related to radiation and benzene convey risks for leukemia independently of each other. The results underline that risk assessments and preventive strategies must include considerations of both genetic and environmental risk factors. Research by Johnson and colleagues (2018) further explored genetic and environmental interactions by focusing on the interaction of a genetic variant at RUNX1 with pesticide exposure. Their research highlighted how individual predisposition might further strengthen the impact of ambient toxicants and the relevance of individualized prevention strategies based on genetic predisposing factors and environmental exposures (Johnson et al., 2018). Additional research has expanded on this discussion by investigating genetic syndromes, such as Down syndrome and Li-Fraumeni syndrome, that increase leukemia risk and highlight the necessity of targeted screening and monitoring. Overall these findings contributed to a more nuanced understanding of leukemia risks, emphasizing the value of integrating genetic and environmental data in strategies for prevention and intervention. Future studies should focus on further refinement, exploring other environmental factors and genetic conditions to improve the accuracy of leukemia risk assessments and prevention efforts.

Understanding genetic risk factors is paramount for advancing the field of pediatric oncology. By identifying how RUNX1, TP53, and BRCA1 increase the risk of developing leukemia, researchers and clinicians can better identify genetic risks in patients and develop targeted therapies to address these specific mutations (Chen et al., 2022; Fair et al., 2023). This research not only holds the promise of improving diagnostic tools but also paves the way for innovative treatment strategies that could enhance outcomes for children diagnosed with leukemia. By focusing on the genetic underpinnings of this disease, scientists hope to transform the landscape of pediatric leukemia treatment, ultimately leading to more effective and personalized care for young patients (Buffler et al., 2005; Kratz et al., 2022).

The persistent effects of environmental toxicants highlight the need for stringent exposure limits, particularly for children. Even low levels of exposure during essential developmental stages can have lasting effects on genomic stability and immune function, both of which contribute to leukemia risk (Kratz et al., 2022). Disruptions in genomic stability can initiate a cascade of cellular events that promote cancer development, underscoring the importance of understanding the molecular pathways through which these environmental factors operate. The need for public health initiatives to reduce environmental exposures to known carcinogens, especially in vulnerable populations like children, cannot be overstated (U.S. Environmental Protection Agency et al., 2024). Stricter regulations on industrial emissions, improved safety standards for pesticide use, and informed decision-making regarding medical imaging in children are essential to safeguard their health (Cedars-Sinai, 2024).

The interplay between genetic and environmental risk factors underscores the need to better understand how specific genetic mutations increase susceptibility to environmental carcinogens and how such exposure can guide the development of targeted public health interventions (Chen et al., 2022). Future studies should also examine other environmental risk factors—such as household chemicals and air pollution. Although Smith et al. (2023) provided significant insights into gene-environment interactions in pediatric leukemia, they noted that self-reported data on environmental exposure may introduce bias.

Literature has emphasized the need for frequent health follow-ups and tailored precautionary measures for children with genetic syndromes (Fair et al., 2023). This research also highlights the necessity for further investigation of other genetic conditions that could increase the risk of developing leukemia and the potential for gene-based therapies in treatment and prevention (Nead et al., 2018). However, the study only focuses on a few genetic conditions, requiring more extensive research to explore other genetic factors (Jackson, 2018). Per the literature, the genetic basis

of pediatric leukemia suggests that genetic testing and therapies could play a significant role in improving treatment outcomes (Fair et al., 2023).

The collaborative efforts of geneticists and environmental scientists strive to unravel the complexities of gene-environment interactions. By identifying specific genetic markers that confer heightened sensitivity to environmental toxins, researchers have advocated for stricter regulations on hazardous substances, thus safeguarding at-risk populations (Casaubon et al., 2024).

Conclusion

In summary, these studies illuminate the multifaceted nature of childhood leukemia, confirming that it is a complex interplay of genetic and environmental factors. Genetic mutations and environmental exposures, like radiation and benzene, are independent risk factors, underscoring the importance of including both in comprehensive risk assessments. Various genetic and environmental factors play a role in the development of childhood leukemia. Genetic alterations such as mutations in RUNX1, TP53, and BRCA1 are vital in the leukemic process due to their role in essential cellular functions, including DNA repair, cell cycle regulation, and blood cell differentiation. Genetic alterations significantly increase the risk for leukemia, especially when combined with environmental exposure to ionizing radiation, benzene, and pesticides, which are toxic to DNA and can disrupt normal hematopoiesis. While moving into the future, there is an essential need for interdisciplinary research that incorporates genetics with environmental factors in the development of better strategies for prevention and targeted interventions. The establishment of genetic vulnerabilities and how they interact with environmental risks will better arm public health policies toward reducing harmful exposures and ultimately improving outcomes in children at risk of leukemia. This comprehensive approach offers promising pathways to mitigate the global burden of leukemia in children and enhance effectiveness in early detection and personalized treatment and prevention strategies.

Limitations

Research in understanding molecular mechanisms and genetic sequences related to pediatric leukemia faces limitations, mainly due to small sample sizes and narrow genetic focus. Many studies primarily concentrate on mutations in well-known genes such as TP53 and BRCA1, which, while informative, may overlook other potential genetic contributors to leukemia susceptibility. These studies often struggle with sample sizes large enough to detect statistically significant interactions between specific genes and environmental exposures. Limiting the scope of research may increase the potential to discover lesser-known pathways. Yet, the potential small sample size may not be generalizable across larger or different populations. Furthermore, technological constraints in sequencing and bioinformatics analysis pose challenges in achieving a comprehensive understanding of the genetic landscape of pediatric leukemia.

Studies investigating environmental influences on leukemia risk frequently focus on individual toxicants, such as radiation or benzene exposure, often in isolation. This single-toxicant approach may not fully capture the cumulative effects of multiple environmental exposures, which are more likely to reflect real-world conditions. Additionally, data on environmental exposure often relies on self-reporting, which introduces recall bias and limits data accuracy. These factors restrict our ability to assess the true impact of environmental contributors associated with the development and progression of pediatric leukemia, further confounded by the variability in individual susceptibility, which is not always accounted for in exposure assessments.

Research on the interplay between genetic predispositions and environmental factors in pediatric leukemia is relatively recent and encounters several methodological challenges. Leukemia is a complex disease with multiple contributing factors, making it difficult to isolate specific gene-environment interactions. The multifactorial nature of leukemia complicates efforts to draw direct links between genetic markers and specific environmental triggers, limiting our understanding of how these elements work in tandem to influence disease risk.

Future Directions

Future research should incorporate larger and more diverse sample populations to address current limitations in understanding genetic factors associated with pediatric leukemia. Expanding the focus to include genome-wide association studies and next-generation sequencing could reveal additional genetic variants contributing to leukemia risk. Furthermore, integrating advanced bioinformatics tools would facilitate further analysis of gene regulatory networks, potentially identifying novel genetic pathways involved in leukemia. These improvements could enhance precision medicine by allowing more targeted prevention and treatment options.

Moreover, future studies on environmental influences should adopt a multi-toxicant approach, examining cumulative exposure to multiple toxicants simultaneously. Leveraging modern tracking technologies, such as wearable sensors, could provide more precise data on long-term environmental exposure, helping to mitigate issues with recall bias. Longitudinal studies that follow individuals over time could also enhance understanding of how chronic exposure to environmental factors influences leukemia risk. By moving beyond single-exposure models, researchers could achieve a more accurate representation of environmental risks associated with pediatric leukemia.

Advancing research on gene-environment interactions in pediatric leukemia requires more extensive, multicenter studies with sufficient statistical power to detect specific interaction effects. Expanding on existing genetic data with environmental assessments could facilitate a more nuanced understanding of how genetic predispositions and external exposures jointly influence leukemia risk. Future studies should focus on developing personalized risk assessment models that consider genetic susceptibility and environmental exposures, which could lead to more effective prevention strategies tailored to individual risk profiles. Additionally, integrating functional studies to investigate the biological mechanisms underlying these interactions would provide insights that could inform targeted interventions.

Acknowledgments

I would like to express my deepest gratitude to Dr. Christie Martin for her unwavering support and guidance in writing this paper. Her incredible knowledge, patience, and encouragement have been a constant source of inspiration, helping me grow both academically and personally.

References

American Cancer Society. (2024). *Risk factors for childhood leukemia*. https://www.cancer.org/cancer/types/leukemia-in-children/causes-risks-prevention/risk-factors.html

Brown, P., Inaba, H., Annesley, C., Beck, J., Colace, S., Dallas, M., DeSantes, K., Kelly, K., Kitko, C., Lacayo, N., Larrier, N., Maese, L., Mahadeo, K., Nanda, R., Nardi, V., Rodriguez, V., Rossoff, J., Schuettpelz, L., Silverman, L., … Ogba, N. (2020). Pediatric acute lymphoblastic leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network*, *18*(1), 81–112. https://doi.org/10.6004/jnccn.2020.0001

Buffler, P., Kwan, M., Reynolds, P., & Urayama, K. (2005). Environmental and genetic risk factors for childhood leukemia: Appraising the evidence. *Cancer Investigation*, *23*(1), 60–75. https://doi.org/10.1081/CNV-200046402

Buser, J. M., Lake, K., & Ginier, E. (2022). Environmental risk factors for childhood cancer in an era of global climate change: A scoping review. *Journal of Pediatric Health Care*, *36*(1), 46–56. https://doi.org/10.1016/j.pedhc.2021.05.005

Casaubon, J. T., Kashyap, S., & Regan, J.-P. (2024). *BRCA1 and BRCA2 Mutations*.

Cedars-Sinai. (2024). Leukemia in children. *Website*. https://www.cedars-sinai.org/health-library/diseases-and-conditions---pediatrics/l/leukemia-in-children.html

Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., Li, Q., Zhang, H., & Di, C. (2022). Mutant p53 in cancer: From molecular mechanism to therapeutic modulation. *Cell Death & Disease*, *13*(11), 974–974. https://doi.org/10.1038/s41419-022-05408-1

de Smith, A. J., Jiménez-Morales, S., & Mejía-Aranguré, J. M. (2024). The genetic risk of acute lymphoblastic leukemia and its implications for children of Latin American origin. *Frontiers in Oncology*, *13*. https://doi.org/10.3389/fonc.2023.1299355

Dreinhöfer, K. E., Åkerman, M., Willén, H., Anderson, C., Gustafson, P., & Rydholm, A. (1994). Proliferating cell nuclear antigen (PCNA) in high-grade malignant fibrous histiocytoma: Prognostic value in 48 patients. *International Journal of Cancer*, *59*(3), 379–382. https://doi.org/10.1002/ijc.2910590315

Fair, D., Maese, L., Chi, Y., Li, M., Hawkins, D. S., Venkatramani, R., Rudzinski, E., Parham, D., Teot, L., Malkin, D., Plon, S. E., Li, H., Sabo, A., Lupo, P. J., & Schiffman, J. D. (2023). TP53 germline pathogenic variant frequency in anaplastic rhabdomyosarcoma: A children's oncology group report. *Pediatric Blood & Cancer*, *70*(9). https://doi.org/10.1002/pbc.30413

Goetz, L. H., & Schork, N. J. (2018). Personalized medicine: Motivation, challenges, and progress. *Fertility and Sterility*, *109*(6), 952–963. https://doi.org/10.1016/j.fertnstert.2018.05.006

Hewelt-Belka, W., Kot-Wasik, Á., Tamagnini, P., & Oliveira, P. (2020). Untargeted lipidomics analysis of the cyanobacterium Synechocystis sp. PCC 6803: Lipid composition variation in response to alternative cultivation setups to gene deletion. *International Journal of Molecular Sciences*, *21*(23), 8883–8883. https://doi.org/10.3390/ijms21238883

Jackson, M., Marks, L., May, G. H. W., & Wilson, J. B. (2018). The genetic basis of disease. *Essays in Biochemistry*, *62*(5), 643–723. https://doi.org/10.1042/EBC20170053

Johnson, K.J., Soler, J.T., Puumala, S.E. *et al.* Parental and infant characteristics and childhood leukemia in Minnesota. *BMC Pediatr* 8, 7 (2008). https://doi.org/10.1186/1471-2431-8-7

Kratz, C. P., Smirnov, D., Autry, R., Jäger, N., Waszak, S. M., Großhennig, A., Berutti, R., Wendorff, M., Hainaut, P., Pfister, S. M., Prokisch, H., Ripperger, T., & Malkin, D. (2022). Heterozygous BRCA1 and BRCA2 and mismatch repair gene pathogenic variants in children and adolescents with cancer. *JNCI: Journal of the National Cancer Institute*, *114*(11), 1523–1532. https://doi.org/10.1093/jnci/djac151

Lee, S. H. R., Yang, W., Gocho, Y., John, A., Rowland, L., Smart, B., Williams, H., Maxwell, D., Hunt, J., Yang, W., Crews, K. R., Roberts, K. G., Jeha, S., Cheng, C., Karol, S. E., Relling, M. V., Rosner, G. L., Inaba, H., Mullighan, C. G., … Yang, J. J. (2023). Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response. *Nature Medicine*, *29*(1), 170–179. https://doi.org/10.1038/s41591-022-02112-7

Lin, T.-C. (2022). RUNX1 and cancer. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, *1877*(3), 188715–188715. https://doi.org/10.1016/j.bbcan.2022.188715

MOFFITT Cancer Center. (2024). Leukemia. *Website*. https://www.moffitt.org/cancers/leukemia/

National Cancer Institute. (2024a). BRCA gene changes: Cancer risk and genetic testing. *Website*. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet

National Cancer Institute. (2024b). Childhood acLymphoblasticstic leukemia (PDQ®)–Patient version. *Website*. https://www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq

Onyije, F. M., Olsson, A., Baaken, D., Erdmann, F., Stanulla, M., Wollschläger, D., & Schüz, J. (2022). Environmental risk factors for childhood acute lymphoblastic leukemia: An umbrella review. *Cancers*, *14*(2), 382–382. https://doi.org/10.3390/cancers14020382

Ramsey, J., Butnor, K., Peng, Z., Leclair, T., van der Velden, J., Stein, G., Lian, J., & Kinsey, C. M. (2018). Loss of RUNX1 is associated with aggressive lung adenocarcinomas. *Journal of Cellular Physiology*, *233*(4), 3487–3497. https://doi.org/10.1002/jcp.26201

Siegel, D. A., Li, J., Henley, S. J., Wilson, R. J., Lunsford, N. B., Tai, E., & Van Dyne, E. A. (2018). Geographic variation in pediatric cancer incidence—United States, 2003–2014. *MMWR. Morbidity and Mortality Weekly Report*, *67*(25), 707–713. https://doi.org/10.15585/mmwr.mm6725a2

St. Luke's. (2024). BRCA. *Website*. https://www.saintlukeskc.org/health-library/brca

Ueno, H., Yoshida, K., Shiozawa, Y., Nannya, Y., Iijima-Yamashita, Y., Kiyokawa, N., Shiraishi, Y., Chiba, K., Tanaka, H., Isobe, T., Seki, M., Kimura, S., Makishima, H., Kakiuchi, N., Kataoka, K., Yoshizato, T., Tsukamoto, H., Nishijima, D., Deguchi, T., … Sanada, M. (2018). The prognostic value of TP53 mutations depends on clinical backgrounds in pediatric patients with acute lymphoblastic leukemia. *Blood*, *132*(Supplement 1), 4077–4077. https://doi.org/10.1182/blood-2018-99-115617

United States Environmental Protection Agency. (2024). EPA efforts to reduce exposure to carcinogens and prevent cancer. *Website*. https://www.epa.gov/environmental-topics/epa-efforts-reduce-exposure-carcinogens-and-prevent-cancer

Villegas-Ruíz, V., Medina-Vera, I., Arellano-Perdomo, P., Castillo-Villanueva, A., Galván-Diaz, C. A., Paredes-Aguilera, R., Rivera-Luna, R., & Juárez-Méndez, S. (2023). Low expression of BRCA1 as a potential relapse predictor in B-Cell acute lymphoblastic leukemia. *Journal of Pediatric Hematology/Oncology*, *45*(2), e167–e173. https://doi.org/10.1097/MPH.0000000000002595